PHARMAC and erythropoietin for cancer patients
Grocott, R.; Metcalfe, S.; Moodie, P.
New Zealand Medical Journal 119(1236): U2039
2006
ISSN/ISBN: 1175-8716 PMID: 16807581 Document Number: 596405
Document emailed within 1 workday
Related Documents
Gara, S.; Ghanem, A.; Jmal, A.; Loussaïef, W.; Gara, Y.; Baaboura, R.; Mtaallah, H.; Harzallah, L.; Abbes, S.; Abdennebi, M.; Guemira, F. 2007: Erythropoietin in cancer patients with anemia La Tunisie Medicale 85(2): 131-133Doweiko, J.P.; Goldberg, M.A. 1991: Erythropoietin therapy in cancer patients Oncology 5(8): 31-37; Discussion 38: 43-44
Wood, P.A.; Hrushesky, W.J. 1995: Erythropoietin usage in patients with cancer Cancer Journal from Scientific American 1(4): 243-246
Yurut-Caloglu, V.; Haydaroglu, A.; Ozkok, S.; Yalman, D.; Bolukbasi, Y. 2009: Erythropoietin and radiotherapy in lung cancer patients Journal of Buon: Official Journal of the Balkan Union of Oncology 14(3): 519-521
Spivak, J.L. 1992: The application of recombinant erythropoietin in anemic patients with cancer Seminars in Oncology 19(3 Suppl 8: 25-28
Abels, R.I. 1992: Use of recombinant human erythropoietin in the treatment of anemia in patients who have cancer Seminars in Oncology 19(3 Suppl 8: 29-35
Henry, D.H. 1993: Recombinant human erythropoietin for the treatment of anemia in patients with advanced cancer Seminars in Hematology 30(4 Suppl 6: 12-16
Bösze, P.; Mayer, A.; Thurzó, L.; Kiss, A.; Rák, K.; Stumpf, J. 1995: Recombinant human erythropoietin in the treatment of anemic patients undergoing chemotherapy for cancer Orvosi Hetilap 136(47): 2567-2572
Lastiri, Jé.M.; Specterman, S.R.; Rendo, P.; Pallotta, Mía.G.; Varela, M.S.; Goldstein, Sía. 2002: Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer Medicina 62(1): 41-47
Dempke, W. 2007: Preclinical and clinical effects of erythropoietin in the management of anaemia in patients with non-small cell lung cancer Anticancer Research 27(4a): 1745-1757
Queipo Zaragozá, J.é A.; Chicote Pérez, F.; Beltrán Meseguer, J.F.; Borrell Palanca, A.; Giner Marco, V.; Esteve Claramunt, J.ús.; Pastor Sempere, F. 2004: Improvement of anemia and quality of life of patients with prostate cancer by treatment with human recombinant erythropoietin Archivos Espanoles de Urologia 57(1): 35-40
Beguin, Y. 2002: Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients Haematologica 87(11): 1209-1221
Roungrong, J.; Teerawattananon, Y.; Chaikledkaew, U. 2008: Cost-utility analysis of recombinant human erythropoietin in anemic cancer patients induced by chemotherapy in Thailand Journal of the Medical Association of Thailand 91(Suppl 2): S119-S125
Laupacis, A. 1991: A randomized double-blind study of recombinant human erythropoietin in anaemic hemodialysis patients. Canadian Erythropoietin Study Group Transplantation Proceedings 23(2): 1825-1826
Satirapoj, B.; Supasyndh, O.; Choovichian, P. 2014: A comparative study of efficacy and safety of the lyophilized powder alpha-erythropoietin and the liquid form alpha-erythropoietin for hemoglobin maintenance in patients with hemodialysis treatment Journal of the Medical Association of Thailand 97(9): 899-906
Braczkowski, R.; Romanawsky, W.; Danikiewicz, A.; Muc-Wierzgon, M.; Błazelonis, A.; Zubelewicz, B. 2001: Decrease of erythropoietin level by human recombinant tumour necrosis factor alpha (hrec TNFalpha) in patients with advanced cancer Journal of Biological Regulators and Homeostatic Agents 15(4): 366-369
Bennett, W.; McNee, W. 1998: PHARMAC and statins New Zealand Medical Journal 111(1077): 439-440
Metcalfe, S.; Moodie, P.; Davies, A.; McNee, W.; Dougherty, S. 2005: PHARMAC responds on salbutamol New Zealand Medical Journal 118(1221): U1644
Haddad, P. 1999: PHARMAC complicates treatment of glaucoma New Zealand Medical Journal 112(1099): 434
Reinhart, W.H. 1994: Shear stress modulates erythropoietin secretion and explains unexpectedly low erythropoietin levels Journal of Laboratory and Clinical Medicine 123(6): 930-931